1. Home
  2. TENX vs CMMB Comparison

TENX vs CMMB Comparison

Compare TENX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TENX
  • CMMB
  • Stock Information
  • Founded
  • TENX 1967
  • CMMB 2004
  • Country
  • TENX United States
  • CMMB Israel
  • Employees
  • TENX N/A
  • CMMB N/A
  • Industry
  • TENX Biotechnology: Pharmaceutical Preparations
  • CMMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • TENX Health Care
  • CMMB Health Care
  • Exchange
  • TENX Nasdaq
  • CMMB Nasdaq
  • Market Cap
  • TENX 19.5M
  • CMMB N/A
  • IPO Year
  • TENX N/A
  • CMMB N/A
  • Fundamental
  • Price
  • TENX $5.61
  • CMMB $1.68
  • Analyst Decision
  • TENX Strong Buy
  • CMMB Strong Buy
  • Analyst Count
  • TENX 4
  • CMMB 3
  • Target Price
  • TENX $20.67
  • CMMB $7.33
  • AVG Volume (30 Days)
  • TENX 67.4K
  • CMMB 87.3K
  • Earning Date
  • TENX 11-13-2024
  • CMMB 11-14-2024
  • Dividend Yield
  • TENX N/A
  • CMMB N/A
  • EPS Growth
  • TENX N/A
  • CMMB N/A
  • EPS
  • TENX N/A
  • CMMB N/A
  • Revenue
  • TENX N/A
  • CMMB N/A
  • Revenue This Year
  • TENX N/A
  • CMMB N/A
  • Revenue Next Year
  • TENX N/A
  • CMMB N/A
  • P/E Ratio
  • TENX N/A
  • CMMB N/A
  • Revenue Growth
  • TENX N/A
  • CMMB N/A
  • 52 Week Low
  • TENX $2.77
  • CMMB $0.45
  • 52 Week High
  • TENX $27.36
  • CMMB $2.55
  • Technical
  • Relative Strength Index (RSI)
  • TENX 54.30
  • CMMB 52.44
  • Support Level
  • TENX $5.70
  • CMMB $1.53
  • Resistance Level
  • TENX $6.01
  • CMMB $1.71
  • Average True Range (ATR)
  • TENX 0.47
  • CMMB 0.11
  • MACD
  • TENX -0.08
  • CMMB -0.01
  • Stochastic Oscillator
  • TENX 12.15
  • CMMB 39.47

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Share on Social Networks: